SUNSHINE PHARMA(06887.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
SUNSHINE PHARMA
06887.HK
Sunshine Lake Pharma Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products for the treatment of infectious diseases, chronic diseases, and oncology. It offers Kewei for the treatment of influenza; Dongweien for the treatment of hepatitis C; and generic drugs for the treatment of infections caused by sensitive bacteria, namely Clarithromycin, Levofloxacin, and Moxifloxacin Hydrochlorid, as well as active pharmaceutical ingredients. The company also engages in the wholesale, retail, import, and export of drugs.
1.454 T
06887.HKMarket value -Rank by Market Cap -/-

Financial Score

29/01/2026 Update
C
PharmaceuticalsIndustry
Industry Ranking18/48
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE5.87%C
    • Profit Margin12.96%B
    • Gross Margin75.03%A
  • Growth ScoreE
    • Revenue YoY-41.69%E
    • Net Profit YoY-76.12%E
    • Total Assets YoY-5.69%D
    • Net Assets YoY3.68%C
  • Cash ScoreD
    • Cash Flow Margin771.43%B
    • OCF YoY-41.69%E
  • Operating ScoreD
    • Turnover0.3D
  • Debt ScoreB
    • Gearing Ratio31.55%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Sunshine Lake Pharma Signs AI Drug R&D Framework with Shenzhen XtalPi

    Sunshine Lake Pharma Signs AI Drug R&D Framework with Shenzhen XtalPi

    marketscreener·
    SH
    520690
    -0.69%
    SH
    513120
    -0.99%
    SH
    513700
    -1.03%
    marketscreener·
    SH
    520690
    -0.69%
    SH
    513120
    -0.99%
    SH
    513700
    -1.03%

    Morning Trend | SUNSHINE PHARMA under pressure, when will the oversold rebound window arrive?

    On January 21st, Dongxing Securities Co., Ltd. (6887.HK) fluctuated weakly at a low level throughout the day, with sporadic buying and no significant capital inflow observed. The atmosphere of wait-and-see remains strong. The short-term MACD death cross pressure is significant, with green bars continuously extending. Although there is an oversold condition, the main capital has not shown clear buying actions. The entire biopharmaceutical sector has been dragged down by medical insurance centralized procurement and policy adjustments, leading to a significant decline in investment enthusiasm. Dongxing Securities Co., Ltd. also has no major clinical progress or large order announcements disclosed, and the sector's speculative points have cooled down from last year's highs. Strategic funds tend to favor short-term trading based on intraday fluctuations, with no clear overnight holding intentions, and market risk appetite continues to decline. 12.10 yuan has become a key observation point for the short term, and a volume decrease breaking through this level indicates that the bearish forces still have room for release. The intraday chart occasionally shows technical rebounds, but the trading volume has not effectively expanded, lacking sustained follow-up buying. In the overall weak pattern, the oversold rebound window still needs to wait for sector funds and industry event catalysts. In the short term, it is recommended to pay attention to sector fund dynamics, new drug research and development progress, and policy news. Before market sentiment repairs or event-driven signals appear, right-side traders should still prioritize safety margins to prevent additional losses from short-term abnormal fluctuations

    Technical Forecast·
    HK
    06887
    -5.89%
    Technical Forecast·
    HK
    06887
    -5.89%
    © 2026 Longbridge｜Disclaimer